TG Therapeutics to Present BRIUMVI Data at ECTRIMS 2025 Meeting

TG Therapeutics will present data on BRIUMVI (ublituximab-xiiy) at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. The presentations will focus on the long-term efficacy and safety of ublituximab in relapsing multiple sclerosis patients from the ULTIMATE I and II open-label extension. The first presentation will be on September 24th at 14:55-15:05 CEST.

TG Therapeutics (NASDAQ: TGTX) has announced a series of presentations at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, focusing on BRIUMVI® (ublituximab-xiiy). The company will present data on the long-term efficacy and safety of ublituximab in patients with relapsing multiple sclerosis (RMS) from the ULTIMATE I and II open-label extension trials.

The first presentation, titled "Long-term Efficacy and Safety of Ublituximab in Relapsing Multiple Sclerosis: Results from Six Years of ULTIMATE I and II Open-label Extension," will take place on September 24th at 14:55-15:05 CEST. This presentation will provide insights into the long-term effects of ublituximab, a novel monoclonal antibody targeting CD20-expressing B-cells, in the management of RMS. The study, led by Lawrence Steinman, MD, of Stanford University, enrolled 1,094 patients across 10 countries and followed patients for six years TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting^[1].

The ULTIMATE I and II trials, which enrolled patients with RMS who experienced at least one relapse in the previous year or had a T1 gadolinium (Gd)-enhancing lesion in the previous year, compared ublituximab to teriflunomide, an oral medication commonly used to treat RMS. The results of these trials are expected to offer valuable information on the long-term efficacy and safety of ublituximab in managing RMS, a chronic autoimmune disorder affecting the central nervous system.

In addition to the oral presentation, TG Therapeutics will also present two ePosters at ECTRIMS 2025. The first ePoster, titled "Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates from the ENHANCE Study," will discuss the safety and tolerability of a modified dosing regimen for ublituximab. The second ePoster, titled "Real-World Clinical Experience from ENABLE: the First Phase 4 Observational Study for Patients with Relapsing Multiple Sclerosis Initiating Ublituximab," will present real-world clinical experience from the ENABLE Phase 4 observational study.

All presentations will be available on TG Therapeutics' website after the conference. The company's pipeline section will include the data presented at the ECTRIMS 2025 meeting, providing investors and financial professionals with a comprehensive overview of the company's progress in developing ublituximab for the treatment of RMS.

These presentations are significant for TG Therapeutics, as they provide an opportunity to share the latest research findings on ublituximab and its potential as a treatment for RMS. The data presented at ECTRIMS 2025 will be crucial for evaluating the long-term efficacy and safety of ublituximab, as well as its potential role in the treatment landscape for RMS.

References:
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting^[1] TG Therapeutics, Inc. (NASDAQ: TGTX). (2025). TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® at ECTRIMS 2025. Globe Newswire. Retrieved from https://www.stocktitan.net/news/TGTX/tg-therapeutics-announces-schedule-of-data-presentations-for-briumvi-qyw6goyf1k5f.html